Bicara Therapeutics Inc. filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing bifunctional therapies for solid tumors. Forms 8-K record financial results, business highlights, ficerafusp alfa clinical updates, material definitive agreements and other events, including common stock and pre-funded warrant financing.
The company’s proxy materials cover annual meeting proposals, board-class elections, auditor ratification and governance matters for an emerging growth company. The filings also describe capital-structure actions and formal exhibits tied to press releases, underwriting agreements and shareholder voting matters.
Bicara Therapeutics Inc. (BCAX) filed a Form 144 notifying a proposed sale of 39,600 common shares through UBS Financial Services on 10/06/2025 with an aggregate market value of $714,997.10. The filing shows two acquisition dates: 05/12/2024 for 15,600 shares from a nonqualified option exercise paid in cash, and 10/06/2025 for 24,000 shares from an NQSO also paid in cash. The total outstanding shares reported are 54,562,841, which places the proposed sale at roughly 0.07% of outstanding common stock. No sales by the reporting person in the prior three months were reported, and the filer states they are not aware of any undisclosed material adverse information.
Bicara Therapeutics, Inc. (BCAX) filed a Form 144 notifying a proposed sale of 6,514 common shares, with an aggregate market value of $110,998, listing the intended sale date as 10/06/2025 on NASDAQ. The filing shows these shares were acquired and paid for on 10/06/2025 through the exercise of stock options from the issuer, with payment in cash. The filer reports no securities sold in the prior three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.
Bicara Therapeutics, Inc. (BCAX) has filed a registration statement on Form S-3 establishing a shelf for securities and incorporates by reference prior SEC filings including its Form 10-K and amendments. The prospectus discloses clinical data for an HPV-negative HNSCC population with a PD-L1 combined positive score ≥1 and reports a 2-year overall survival rate of 46%. The document describes tax and withholding rules for non-U.S. holders, including a 30% default U.S. withholding rate and treaty-reduced rates where applicable. The filing lists underwriting and sales agreements, corporate charters and bylaws, opinions from Goodwin Procter LLP, consent from KPMG LLP, and trustee eligibility statements. Multiple exhibits and effective dates, including signatures dated October 3, 2025, are included.
Lara Meisner, Chief Legal Officer of Bicara Therapeutics (BCAX), reported option exercise and an immediate sale on 09/29/2025 under a pre-established plan. The reporting person exercised a stock option with a $9.2435 exercise price to acquire 33,807 shares and concurrently sold 33,807 shares at $14.75 per share, leaving 0 shares of common stock held directly after the sale. The option granting those shares vests on a schedule that began with a 25% vesting on 08/13/2025 and continues in twelve equal quarterly installments; the option expires 08/13/2034. The filing notes the transactions were executed pursuant to a Rule 10b5-1 trading plan adopted November 13, 2024.
Bicara Therapeutics (BCAX) Form 144 reports a proposed sale of 33,807 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $395,879.97, representing part of the issuer's outstanding 54,562,841 shares. The shares were acquired and will be sold on 09/29/2025 upon exercise of stock options, with payment in cash. The filing also discloses 10b5-1 plan sales by Lara Meisner of 15,829 shares on 09/15/2025 for gross proceeds of $181,893.96. The filer attests there is no undisclosed material adverse information and includes standard Rule 144 and 10b5-1 representations.
Lara Meisner, Chief Legal Officer and director of Bicara Therapeutics (BCAX), reported insider transactions on 09/15/2025 executed under a Rule 10b5-1 trading plan adopted on 11/13/2024. She acquired 15,829 shares of Common Stock at an exercise price of $5.45 and simultaneously sold 15,829 shares at a weighted-average price of $11.49, with sale prices ranging from $11.34 to $11.73.
The filing also discloses two stock option grants exercisable at $5.45 that were affected by the transactions: one covering 6,085 underlying shares and another covering 9,744 underlying shares, each with vesting schedules described in the filing and expiration dates of 12/14/2033.
Vestal Point Capital, LP and Ryan Wilder report ownership of 5,000,000 shares of Bicara Therapeutics Inc. common stock, representing 9.2% of the outstanding shares based on 54,536,218 shares outstanding as of May 8, 2025. The reported interest is held by the Vestal Point fund and a managed account and is shown as shared voting and dispositive power (no sole voting or dispositive power).
The filing identifies Vestal Point as an investment manager and Mr. Wilder as its Chief Investment Officer and managing member. The Reporting Persons state the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Bicara Therapeutics is a clinical-stage biopharmaceutical company advancing its lead bifunctional antibody, ficerafusp alfa, into late-stage testing. The company reported $436.6 million in cash and cash equivalents as of June 30, 2025 and an accumulated deficit of $285.3 million. Net losses were $27.4 million for the quarter and $64.2 million for the six months ended June 30, 2025, driven by higher research and development and general and administrative spending as Bicara scales clinical operations and manufacturing.
Bicara initiated the pivotal FORTIFI-HN01 Phase 2/3 program (combination with pembrolizumab) and maintains a collaboration with MSD to supply pembrolizumab for combination cohorts. R&D spending increased materially to support clinical and manufacturing activity, and management expects existing cash to fund operations into the first half of 2029. The company disclosed pending litigation alleging inventorship of patents and reiterated that it will require additional funding over time to advance development and commercialization.
Bicara Therapeutics Inc. filed a current report to note that it has released its financial results and business highlights for the quarter ended June 30, 2025. On August 12, 2025, the company issued a press release describing its quarterly performance and key developments.
The press release is attached as Exhibit 99.1 and is incorporated by reference for informational purposes, but is designated as furnished rather than filed under the Exchange Act. The filing also includes an Inline XBRL cover page data file as Exhibit 104.
Schedule 13G/A (Am. No. 1) filed for Bicara Therapeutics Inc. (BCAX) shows that investment entities affiliated with Invus have built a passive 9.6 % stake in the company’s common stock as of 30 Jun 2025.
- Invus Public Equities, L.P. directly owns 4,861,944 shares (8.9 %).
- Avicenna Life Sci Master Fund LP holds 355,025 shares (0.7 %).
- Through control of multiple GP/LLC vehicles, Raymond Debbane is deemed to beneficially own a combined 5,216,969 shares, representing the full 9.6 %.
Percentages are based on 54,536,218 shares outstanding reported in the issuer’s 13 May 2025 10-Q. The filing is made under Rule 13d-1(c) and includes the standard certification that the securities were not acquired to change or influence control, indicating a passive investment approach.
The appearance of a sophisticated life-sciences investor just below the 10 % threshold may improve market confidence and liquidity but does not signal activist intent at this stage.